Back to News
Market Impact: 0.25
Mayne Pharma Settles IMVEXXY Patent Litigation With Sun Pharma
Source: Nasdaq
Legal & LitigationPatents & Intellectual PropertyHealthcare & Biotech
Mayne Pharma and Sun Pharmaceutical reached a settlement resolving Paragraph IV patent litigation related to IMVEXXY estradiol vaginal inserts and the product's U.S. FDA Orange Book-listed patents. The resolution removes a legal overhang for Mayne Pharma's IMVEXXY franchise, although financial terms and commercialization implications were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- UK Prime Minister Burnham says Iran 'played a part' in British air base incident
- US judge approves settlement allowing Paramount to acquire Warner Bros
- PHC Holdings surge to near 4-year high after Toho takeover proposal confirmed
- Why is Nidec stock plunging today?
- Nidec Corp shares slump after auditor declines to sign off on earnings
- OpenAI is sued over rogue AI Hugging Face cyberattack
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search
- Automating Financial Model Updates: A Source-Controlled Workflow